Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant
出版年份 2020 全文链接
标题
Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant
作者
关键词
Non-small cell lung cancer, KIF5B-RET, CCDC6-RET, RET inhibitor, Structure-activity relationship
出版物
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 207, Issue -, Pages 112755
出版商
Elsevier BV
发表日期
2020-08-23
DOI
10.1016/j.ejmech.2020.112755
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Selective RET kinase inhibition for patients with RET-altered cancers
- (2018) V Subbiah et al. ANNALS OF ONCOLOGY
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Precision Targeted Therapy with BLU-667 for RET -Driven Cancers
- (2018) Vivek Subbiah et al. Cancer Discovery
- Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
- (2017) Alexander Drilon et al. Nature Reviews Clinical Oncology
- Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors
- (2017) Dennis Plenker et al. Science Translational Medicine
- Enriching screening libraries with bioactive fragment space
- (2016) Na Zhang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
- (2016) Shumei Kato et al. CLINICAL CANCER RESEARCH
- RET kinase inhibitors: a review of recent patents (2012–2015)
- (2016) Luca Mologni et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma
- (2016) Cristina Romei et al. Nature Reviews Endocrinology
- PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
- (2015) Helen Y. Zou et al. CANCER CELL
- A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants
- (2015) Hojong Yoon et al. JOURNAL OF MEDICINAL CHEMISTRY
- Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion
- (2015) Tzu-Hsiu Tsai et al. LUNG CANCER
- Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
- (2014) Zheng Zhao et al. ACS Chemical Biology
- RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
- (2014) K Tsuta et al. BRITISH JOURNAL OF CANCER
- Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors
- (2014) R. S. K. Vijayan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non-Small Cell Lung Cancer
- (2014) T. Kodama et al. MOLECULAR CANCER THERAPEUTICS
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design
- (2013) Javier Blanc et al. Anti-Cancer Agents in Medicinal Chemistry
- Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
- (2013) Kiyoshi Okamoto et al. CANCER LETTERS
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase
- (2013) Luca Mologni et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
- (2013) J. F. Gainor et al. ONCOLOGIST
- KIF5B-RET fusions in lung adenocarcinoma
- (2012) Takashi Kohno et al. NATURE MEDICINE
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
- (2011) Theonie Anastassiadis et al. NATURE BIOTECHNOLOGY
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition
- (2008) AC Backes et al. Expert Opinion on Drug Discovery
- Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition
- (2008) AC Backes et al. Expert Opinion on Drug Discovery
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started